Frank Stokes Net Worth

The estimated Net Worth of Frank Stokes is at least $2.71 Million dollars as of 7 August 2024. Mr. Stokes owns over 10,000 units of Castle Biosciences stock worth over $956,438 and over the last 5 years he sold CSTL stock worth over $257,000. In addition, he makes $1,498,230 as Chief Financial Officer at Castle Biosciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Stokes CSTL stock SEC Form 4 insiders trading

Frank has made over 11 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of CSTL stock worth $257,000 on 7 August 2024.

The largest trade he's ever made was exercising 26,000 units of Castle Biosciences stock on 13 October 2020 worth over $62,140. On average, Frank trades about 6,748 units every 71 days since 2019. As of 7 August 2024 he still owns at least 30,823 units of Castle Biosciences stock.

You can see the complete history of Mr. Stokes stock trades at the bottom of the page.

Frank Stokes biography

Frank Stokes serves as Chief Financial Officer of the Company. From January 2017 to December 2017, Mr. Stokes served as Chief Financial Officer of Hammock Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of women’s health and urology products. From May 2011 to December 2016, Mr. Stokes served as a Managing Director of Leerink Swann (now SVB Leerink). Mr. Stokes also held positions as a Managing Director at Robert W. Baird & Co. Incorporated and Wachovia Securities, LLC. While at SVB Leerink and Robert W. Baird & Co., Mr. Stokes led life sciences, tools and diagnostics sector investment banking efforts, and managed financings and mergers and acquisitions transactions. Mr. Stokes holds a B.S. degree in Business Administration and J.D. and MBA degrees from the University of North Carolina at Chapel Hill.

What is the salary of Frank Stokes?

As the Chief Financial Officer of Castle Biosciences, the total compensation of Frank Stokes at Castle Biosciences is $1,498,230. There are 1 executives at Castle Biosciences getting paid more, with Derek Maetzold having the highest compensation of $4,132,350.

How old is Frank Stokes?

Frank Stokes is 50, he's been the Chief Financial Officer of Castle Biosciences since 2017. There are 11 older and 2 younger executives at Castle Biosciences. The oldest executive at Castle Biosciences, Inc. is David Kabakoff, 72, who is the Independent Director.

What's Frank Stokes's mailing address?

Frank's mailing address filed with the SEC is C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD, TX, 77546.

Insiders trading at Castle Biosciences

Over the last 5 years, insiders at Castle Biosciences have traded over $378,509,770 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold und Joseph C. Iii Cook. On average, Castle Biosciences executives and independent directors trade stock every 6 days with the average trade being worth of $632,640. The most recent stock trade was executed by Derek J Maetzold on 9 September 2024, trading 2,586 units of CSTL stock currently worth $76,184.

What does Castle Biosciences do?

Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Complete history of Mr. Stokes stock trades at Exagen Inc und Castle Biosciences

Castle Biosciences executives and stock owners

Castle Biosciences executives and other stock owners filed with the SEC include:

• Derek Maetzold,
  President, Chief Executive Officer, Founder, Director
• Frank Stokes,
  Chief Financial Officer
• Derek J. Maetzold,
  Founder, CEO, Pres & Director
• Frank Stokes,
  Chief Financial Officer
• G. Bradley Cole,
  Independent Director
• Mara Aspinall,
  Independent Director
• Daniel Bradbury,
  Independent Chairman of the Board
• David Kabakoff,
  Independent Director
• Joseph Cook,
  Independent Director
• Miles Harrison,
  Independent Director
• Bernhard Spiess,
  Chief Business Officer
• Noreen Manning,
  Executive Director - Reimbursement
• Michael Maltby,
  Executive Director - Managed Care
• Bob Cook,
  Vice President - Research & Development
• Alice Izzo,
  Vice President - Marketing
• Kristen Oelschlager,
  Senior Vice President - Clinical Operations
• Toby Juvenal,
  Senior Vice President - Sales
• Dr. Robert W. Cook Ph.D.,
  Sr. VP of R&D
• Toby W. Juvenal,
  Chief Commercial Officer
• Camilla Zuckero,
  Exec. Director of Investor Relations & Corp. Communications
• Kristen M. Oelschlager R.N., RN,
  Chief Operating Officer
• Tobin W Juvenal,
  Chief Commercial Officer
• Rodney Cotton,
  Director
• Tiffany Olson,
  Director
• Bonnie H Anderson,
  Director
• Health Quest Partners, L.P....,
  
• Federico A. Monzon,
  Chief Medical Officer
• Venture Partners 2013 Gp, L...,
  
• Kim Caple,
  Director
• Ellen Goldberg,
  Director